The criteria for establishing pleaded standards in a lawsuit primarily focused on the hypertension drug, Bystolic, is currently being scrutinized by an appellate panel of the Second Circuit. This follows a judge’s remarks that one of the alleged reverse payments central to the pharmaceutical antitrust case echoes suspiciously of money laundering operations.
While the antitrust case in question involves a range of complex and intricate legal proceedings, the acknowledgment of possible illicit activity by a Second Circuit judge underscores the severity of the allegations involved.
For more detailed context and examination of the ongoing proceedings, the initial reporting of this incidence can be found on Law360.